Lucile Packard Children's Hospital Logo
Stanford Health Clinics
Stanford School of Medicine
Lucile Packard Foundation for Children's Health
Clinical Specialties Find A Doctor Health Library For Patients & Visitors For Physicians & Health Professionals Jobs & Volunteering News, Events & Classes Directions & Parking Espanol
Home Contact Us Site Index About Us Kids Make a Gift Search
 
Center for Down Syndrome
Genetics Clinic
Metabolic/Biochemical Genetics Clinic
Medical Geneticists
Medical Genetics
New Prenatal Test for Down Syndrome Less Risky than Amniocentesis, Stanford/Packard Scientists Say
Mice with Gene Deletion Provide Clues to Prader-Willi Syndrome in Stanford/Packard Study
Once-Fatal Metabolic Disorders Treatable, Says Stanford/Packard Researcher
 

Medical Genetics

Identifying Teratogens

What studies are conducted to determine whether an agent is a teratogen?

The following studies may be conducted to determine whether or not an agent is a teratogen:

  • Animal studies
    Animal studies are the primary study method to determine whether a medication, or other environmental exposure, is safe during human pregnancy. In the past, there have been medications on the market that humans used which caused birth defects, such as thalidomide in the 1960's. Thalidomide was removed from the market after several babies were born with missing and malformed limbs to mothers who took thalidomide early in pregnancy. Thalidomide has recently been approved by the FDA for the treatment of certain diseases, but it is only available by a physician's prescription.
  • Observations from human exposure
    Observations from human exposure (prior to federal regulations for drug testing) are another important way to determine whether a medication is a teratogen. The official criteria for determining whether an agent is teratogenic in humans was determined by Koch in 1971. They are known as Koch's Postulates:

    1. The agent must be present during the critical stage of development.

    2. The agent produces a particular pattern of birth defects in animal studies.

    3. The agent crosses the placenta and there is a dose-response relationship.

    4. There is an abrupt increase in the frequency of a particular defect or group of defects (syndrome).

    5. The increase of defects is associated with the use of a new drug or the widespread exposure to a chemical or environmental change.

    6. There is an absence of other factors to explain the observations.

    7. The mechanism of teratogenesis makes biological sense.

How are medications rated for their safety?

Prior to 1980, most medications included literature that stated that their use in pregnancy had not been approved. The US Food and Drug Administration (FDA) has since created five drug categories, to designate the safety of medications for their use during pregnancy, including the following. Always consult your physician before taking any medication during pregnancy.


Category Description
A Medication has not shown an increased risk for birth defects in human studies.
B Animal studies have not demonstrated a risk and there are no adequate studies in humans, OR animal studies have shown a risk, but the risk has not been seen in humans.
C Animal studies have shown adverse effects, but no studies are available in humans, OR studies in humans and animals are not available.
D Medications that are associated with birth defects in humans, however, there may be potential benefits in rare cases that outweigh their known risks.
X Medications are contraindicated (should not be used) in human pregnancy, because of known fetal abnormalities that have been demonstrated in both human and animal studies.

 

There have been thousands of medications studied over the years, and only about 30 to 40 have been found to have teratogenic effects in humans. It is always important, however, for a woman who thinks she could be pregnant, or is pregnant, to ask her physician about the safety of a medication or over-the-counter medication, vitamin, mineral, or herbal supplement before taking it.




The information on this Web page is provided for educational purposes. You understand and agree that this information is not intended to be, and should not be used as, a substitute for medical treatment by a health care professional. You agree that Lucile Salter Packard Children’s Hospital is not making a diagnosis of your condition or a recommendation about the course of treatment for your particular circumstances through the use of this Web page. You agree to be solely responsible for your use of this Web page and the information contained on this page. Lucile Salter Packard Children’s Hospital, its officers, directors, employees, agents, and information providers shall not be liable for any damages you may suffer or cause through your use of this page even if advised of the possibility of such damages.


Lucile Packard Children's Hospital is located in Palo Alto, adjacent to Stanford University Hospital, approximately 20 miles north of San Jose, CA and 40 miles south of San Francisco.


Lucile Packard Children's Hospital
725 Welch Road
Palo Alto, California 94304
(650) 497-8000


Copyright 2008 Lucile Packard Children's Hospital. All rights reserved.
Legal Notices & Disclaimers